Hodgkin's Lymphoma Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hodgkin's Lymphoma pipeline constitutes 15+ key companies continuously working towards developing 20 + Hodgkin's Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Hodgkin's Lymphoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hodgkin's Lymphoma Market.

The Hodgkin's Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hodgkin's Lymphoma Pipeline Report: https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Hodgkin's Lymphoma treatment therapies with a considerable amount of success over the years.
• Hodgkin's Lymphoma companies working in the treatment market are Autolus, Genor Biopharma, AbbVie/ Genmab, AstraZeneca, Jiangsu Hengrui Medicine, Pacylex Pharmaceuticals, Zentera Therapeutics, TCR2 Therapeutics, Artiva Biotherapeutics, Loxo Oncology, Angiocrine Bioscience, AbbVie, Novartis, and others, are developing therapies for the Hodgkin's Lymphoma treatment
• Emerging Hodgkin's Lymphoma therapies in the different phases of clinical trials are- AUTO4, GB226, Epcoritamab, Capivasertib, HRS-3738, PCLX-001, ZN-d5, TC-110, AB-101, LOXO-305, AB-205, Venetoclax, Tisagenlecleucel, and others are expected to have a significant impact on the Hodgkin's Lymphoma market in the coming years.
• In June 2025, Nurix Therapeutics shared encouraging clinical results from its ongoing NX-5948-301 Phase Ia/b trial, evaluating bexobrutideg (NX-5948) in patients with relapsed or refractory (R/R) B-cell malignancies.
• In April 2025, Roche reported that the European Commission (EC) has granted approval for COLUMVI, in combination with gemcitabine and oxaliplatin (GemOx), for treating adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified, who are unsuitable for autologous stem cell transplant (ASCT).
• In February 2025, Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has announced the launch of waveLINE-010, a pivotal Phase 3 clinical trial. This study is evaluating the efficacy of zilovertamab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) versus the standard regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zilovertamab vedotin is Merck's investigational antibody-drug conjugate (ADC) designed to target receptor tyrosine kinase-like orphan receptor 1 (ROR1). The global recruitment for the waveLINE-010 trial is underway, and patient enrollment has begun.
• In January 2025, The initial patient with relapsed or refractory B-cell Hodgkin's Lymphoma (B-NHL) has received a dose of SynKIR-310 in the Phase 1 CELESTIAL-301 trial (NCT06544265). This early-stage, multicenter study is designed to assess the safety, tolerability, and preliminary effectiveness of SynKIR-310 in individuals with R/R B-NHL, including subtypes such as diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma.
• In October 2024, ImmunityBio, Inc. (NASDAQ: IBRX), a pioneer in immunotherapy, has announced the initiation of patient dosing in its early-stage clinical trial evaluating the company's CAR-NK cell therapy targeting CD19 for the treatment of non-Hodgkin's lymphoma (NHL). The Phase 1 QUILT 106 trial is assessing CD19-specific high-affinity natural killer (t-haNK) cells, first as a standalone therapy. Upon establishing safety, the treatment will then be combined with rituximab, a standard therapy for NHL, in patients with relapsed or refractory CD19+ and CD20+ B-cell NHL. This open-label study aims to enroll up to 10 participants and is taking place at clinical sites in Johannesburg, Pretoria, and Bloemfontein, South Africa.
• In March 2024, Lantern Pharma initiated dosing for two participants in a Phase Ia/Ib clinical trial assessing its investigational compound LP-284 for individuals with relapsed or refractory non-Hodgkin's lymphoma (NHL). LP-284, a novel small molecule, operates through a synthetically lethal mechanism, targeting cancer cells with mutations in DNA damage repair pathways, ultimately leading to their eradication.

Hodgkin's Lymphoma Overview
Hodgkin's Lymphoma is a type of cancer that originates in the lymphatic system, which is part of the body's immune system. It occurs when abnormal lymphocytes (a type of white blood cell) grow uncontrollably, often forming tumors in lymph nodes, spleen, or other lymphatic tissues. Common symptoms include painless swelling of lymph nodes, fever, night sweats, weight loss, and fatigue. Hodgkin's Lymphoma is relatively rare but is highly treatable, especially when detected early, with treatments including chemotherapy, radiation therapy, and sometimes stem cell transplants.

Get a Free Sample PDF Report to know more about Hodgkin's Lymphoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hodgkins-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Hodgkin's Lymphoma Drugs Under Different Phases of Clinical Development Include:
• AUTO4: Autolus
• GB226: Genor Biopharma
• Epcoritamab: AbbVie/ Genmab
• Capivasertib: AstraZeneca
• HRS-3738: Jiangsu Hengrui Medicine
• PCLX-001: Pacylex Pharmaceuticals
• ZN-d5: Zentera Therapeutics
• TC-110: TCR2 Therapeutics
• AB-101: Artiva Biotherapeutics
• LOXO-305: Loxo Oncology
• AB-205: Angiocrine Bioscience
• Venetoclax: AbbVie
• Tisagenlecleucel: Novartis

Hodgkin's Lymphoma Pipeline Therapeutics Assessment
• Hodgkin's Lymphoma Assessment by Product Type
• Hodgkin's Lymphoma By Stage and Product Type
• Hodgkin's Lymphoma Assessment by Route of Administration
• Hodgkin's Lymphoma By Stage and Route of Administration
• Hodgkin's Lymphoma Assessment by Molecule Type
• Hodgkin's Lymphoma by Stage and Molecule Type

DelveInsight's Hodgkin's Lymphoma Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Hodgkin's Lymphoma product details are provided in the report. Download the Hodgkin's Lymphoma pipeline report to learn more about the emerging Hodgkin's Lymphoma therapies
https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Hodgkin's Lymphoma Therapeutics Market include:
Key companies developing therapies for Hodgkin's Lymphoma are - AstraZeneca, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Eli Lilly and Co., F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC, and others.

Hodgkin's Lymphoma Pipeline Analysis:
The Hodgkin's Lymphoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Hodgkin's Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hodgkin's Lymphoma Treatment.
• Hodgkin's Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hodgkin's Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hodgkin's Lymphoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hodgkin's Lymphoma drugs and therapies
https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hodgkin's Lymphoma Pipeline Market Drivers
• Increasing prevalence, ongoing and increased R&D activity, demand for innovative drugs and novel therapies are some of the important factors that are fueling the Hodgkin's Lymphoma Market.

Hodgkin's Lymphoma Pipeline Market Barriers
• However, high cost of treatment, complications related to the drugs and other factors are creating obstacles in the Hodgkin's Lymphoma Market growth.

Scope of Hodgkin's Lymphoma Pipeline Drug Insight
• Coverage: Global
• Key Hodgkin's Lymphoma Companies: Autolus, Genor Biopharma, AbbVie/ Genmab, AstraZeneca, Jiangsu Hengrui Medicine, Pacylex Pharmaceuticals, Zentera Therapeutics, TCR2 Therapeutics, Artiva Biotherapeutics, Loxo Oncology, Angiocrine Bioscience, AbbVie, Novartis, and others
• Key Hodgkin's Lymphoma Therapies: AUTO4, GB226, Epcoritamab, Capivasertib, HRS-3738, PCLX-001, ZN-d5, TC-110, AB-101, LOXO-305, AB-205, Venetoclax, Tisagenlecleucel, and others
• Hodgkin's Lymphoma Therapeutic Assessment: Hodgkin's Lymphoma current marketed and Hodgkin's Lymphoma emerging therapies
• Hodgkin's Lymphoma Market Dynamics: Hodgkin's Lymphoma market drivers and Hodgkin's Lymphoma market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.